Prosight Management, LP - Q4 2022 holdings

$183 Million is the total value of Prosight Management, LP's 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 89.5% .

 Value Shares↓ Weighting
GLPG BuyGALAPAGOS NVspon adr$20,636,700
+19.5%
465,000
+14.8%
11.25%
+21.6%
PRTA BuyPROTHENA CORP PLC$19,882,500
+2.1%
330,000
+2.8%
10.84%
+4.0%
KZR BuyKEZAR LIFE SCIENCES INC$12,351,180
+8.0%
1,754,429
+32.1%
6.74%
+10.0%
MGTX BuyMEIRAGTX HLDGS PLC$10,650,720
+14.8%
1,633,546
+48.1%
5.81%
+16.8%
ALBO SellALBIREO PHARMA INC$10,518,149
+10.6%
486,726
-0.9%
5.74%
+12.6%
HZNP SellHORIZON THERAPEUTICS PUB L$10,242,000
-45.4%
90,000
-70.3%
5.58%
-44.4%
ALKS SellALKERMES PLC$8,923,944
-20.4%
341,521
-32.0%
4.87%
-19.0%
HUM BuyHUMANA INC$8,836,814
+42.3%
17,253
+34.8%
4.82%
+44.8%
ORIC BuyORIC PHARMACEUTICALS INC$6,950,200
+132.0%
1,180,000
+26.0%
3.79%
+136.1%
MIRM BuyMIRUM PHARMACEUTICALS INC$6,021,132
+0.6%
308,776
+8.3%
3.28%
+2.4%
ALDX SellALDEYRA THERAPEUTICS INC$5,976,615
-7.6%
858,709
-29.1%
3.26%
-5.9%
TNET NewTRINET GROUP INC$5,288,40078,000
+100.0%
2.88%
CUE BuyCUE BIOPHARMA INC$5,245,454
+52.2%
1,840,510
+19.1%
2.86%
+54.9%
STTK BuySHATTUCK LABS INC$4,861,034
+60.6%
2,113,493
+88.6%
2.65%
+63.5%
OPCH NewOPTION CARE HEALTH INC$4,660,881154,898
+100.0%
2.54%
SellQUIDELORTHO CORP$4,283,500
-4.7%
50,000
-20.5%
2.34%
-3.0%
KALV BuyKALVISTA PHARMACEUTICALS INC$4,202,469
-45.4%
621,667
+17.3%
2.29%
-44.4%
HCAT NewHEALTH CATALYST INC$3,696,306347,724
+100.0%
2.02%
ABCL BuyABCELLERA BIOLOGICS INC$3,269,498
+282.0%
322,754
+273.1%
1.78%
+288.5%
GRPH BuyGRAPHITE BIO INC$3,042,973
+169.3%
916,558
+157.1%
1.66%
+174.2%
UNH NewUNITEDHEALTH GROUP INC$2,650,9005,000
+100.0%
1.45%
NTLA NewINTELLIA THERAPEUTICS INC$2,516,12772,116
+100.0%
1.37%
CSII NewCARDIOVASCULAR SYS INC DEL$1,987,376145,916
+100.0%
1.08%
OSH NewOAK STR HEALTH INC$1,806,84084,000
+100.0%
0.98%
ADCT BuyADC THERAPEUTICS SA$1,779,110
+49.0%
463,310
+87.1%
0.97%
+51.6%
NewGALAPAGOS NVcall$1,775,20040,000
+100.0%
0.97%
NewSEAGEN INCcall$1,542,12012,000
+100.0%
0.84%
LFST NewLIFESTANCE HEALTH GROUP INC$1,429,315289,335
+100.0%
0.78%
BCRX BuyBIOCRYST PHARMACEUTICALS INC$1,340,083
-6.5%
116,732
+2.6%
0.73%
-4.8%
BuyCASSAVA SCIENCES INCput$1,208,186
-19.5%
40,900
+13.9%
0.66%
-18.0%
MORF NewMORPHIC HLDG INC$1,148,88642,949
+100.0%
0.63%
AZYO NewAZIYO BIOLOGICS INC$786,310185,014
+100.0%
0.43%
BMEA NewBIOMEA FUSION INC$690,47681,907
+100.0%
0.38%
BBIO NewBRIDGEBIO PHARMA INC$678,38689,027
+100.0%
0.37%
RCKT SellROCKET PHARMACEUTICALS INC$630,017
-80.3%
32,193
-83.9%
0.34%
-79.9%
GOSS NewGOSSAMER BIO INC$575,050265,000
+100.0%
0.31%
EOLS SellEVOLUS INC$498,949
-61.3%
66,438
-58.5%
0.27%
-60.6%
NewTHE ONCOLOGY INSTITUTE INC$454,676275,561
+100.0%
0.25%
NewTENAYA THERAPEUTICS INC$215,197107,063
+100.0%
0.12%
PSNL NewPERSONALIS INC$116,16358,668
+100.0%
0.06%
MRVI ExitMARAVAI LIFESCIENCES HLDGS I$0-8,540
-100.0%
-0.12%
SPOK ExitSPOK HLDGS INC$0-65,000
-100.0%
-0.27%
ExitR1 RCM INC$0-32,113
-100.0%
-0.32%
SBTX ExitSILVERBACK THERAPEUTICS INC$0-196,257
-100.0%
-0.56%
PRQR ExitPROQR THRAPEUTICS N V$0-1,716,290
-100.0%
-0.68%
ARDX ExitARDELYX INC$0-1,126,127
-100.0%
-0.72%
ONEM Exit1LIFE HEALTHCARE INC$0-106,200
-100.0%
-0.98%
RYTM ExitRHYTHM PHARMACEUTICALS INC$0-80,000
-100.0%
-1.05%
BAX ExitBAXTER INTL INC$0-39,000
-100.0%
-1.13%
AVTR ExitAVANTOR INC$0-122,668
-100.0%
-1.29%
OMCL ExitOMNICELL COM$0-30,700
-100.0%
-1.43%
INCY ExitINCYTE CORP$0-40,450
-100.0%
-1.44%
ExitPROTHENA CORP PLCcall$0-53,100
-100.0%
-1.72%
JNJ ExitJOHNSON & JOHNSON$0-31,704
-100.0%
-2.78%
THC ExitTENET HEALTHCARE CORP$0-102,000
-100.0%
-2.82%
CRL ExitCHARLES RIV LABS INTL INC$0-33,220
-100.0%
-3.50%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALDEYRA THERAPEUTICS INC19Q2 20236.2%
ALBIREO PHARMA INC18Q4 20229.2%
MEIRAGTX HOLDINGS PLC18Q3 20236.3%
KEZAR LIFE SCIENCES INC17Q3 20238.2%
ARENA PHARMACEUTICALS INC16Q4 20218.2%
IOVANCE BIOTHERAPEUTICS INC16Q1 20227.7%
CENTENE CORP DEL16Q3 20235.3%
CUE BIOPHARMA INC14Q1 20235.6%
PROTHENA CORP PLC13Q3 202313.6%
ZIMMER BIOMET HOLDINGS INC13Q3 20219.8%

View Prosight Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Prosight Management, LP Q4 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
EXICURE, INC.February 14, 20222,426,5082.2%
Aldeyra Therapeutics, Inc.February 12, 2021908,4882.3%
Teligent, Inc.February 14, 20201,484,5272.8%
Cidara Therapeutics, Inc.February 14, 2019245,7640.9%
Eiger BioPharmaceuticals, Inc.Sold outFebruary 14, 201900.0%
Millendo Therapeutics, Inc.February 14, 2019256,7392.0%
OvaScience, Inc.October 26, 20181,991,1005.6%
CHIMERIX INCFebruary 13, 20181,478,5193.1%
Harvard Apparatus Regenerative Technology, Inc.February 12, 2016184,3601.4%

View Prosight Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G2024-01-02
13F-HR2023-11-14
SC 13G2023-09-01

View Prosight Management, LP's complete filings history.

Compare quarters

Export Prosight Management, LP's holdings